ESPR

3.125

0.32% -0.005

Handel nachbörslich: 3.12 -0.005 -0.16%

Esperion Therapeutics Inc (ESPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ESPR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$3.13

Offen:

$3.13

24-Stunden-Volumen:

6.46M

Relative Volume:

0.60

Marktkapitalisierung:

$804.47M

Einnahmen:

$403.14M

Nettoeinkommen (Verlust:

$-22.68M

KGV:

-14.92

EPS:

-0.2095

Netto-Cashflow:

$-13.09M

1W Leistung:

-0.32%

1M Leistung:

+63.35%

6M Leistung:

-21.01%

1J Leistung:

+294.79%

1-Tages-Spanne:

$3.12

$3.13

1-Wochen-Bereich:

$3.12

$3.14

52-Wochen-Spanne:

$0.792

$4.175

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Firmenname

Esperion Therapeutics Inc

Sektor

Healthcare (1113)

Branche

Drug Manufacturers - Specialty & Generic (86)

Telefon

734-887-3903

Adresse

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Mitarbeiter

294

Twitter

@esperioninc

Nächster Verdiensttermin

2026-05-07

Neueste SEC-Einreichungen

ESPR's Discussions on Twitter

Compare ESPR vs TAK, HLN, TEVA, ZTS, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ESPR Esperion Therapeutics Inc	3.125	805.76M	403.14M	-22.68M	-13.09M	-0.2095
TAK Takeda Pharmaceutical Co Adr	15.87	51.34B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.24	41.15B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.63	39.67B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	80.24	34.09B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	578.43	24.13B	3.17B	1.29B	1.01B	27.09

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-25	Eingeleitet	Piper Sandler	Overweight
2024-12-18	Eingeleitet	Goldman	Neutral
2024-12-17	Eingeleitet	Cantor Fitzgerald	Overweight
2024-06-20	Herabstufung	BofA Securities	Neutral → Underperform
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-01	Hochstufung	Northland Capital	Under Perform → Market Perform
2023-06-15	Hochstufung	BofA Securities	Underperform → Buy
2023-03-16	Herabstufung	BofA Securities	Neutral → Underperform
2023-03-16	Herabstufung	Northland Capital	Market Perform → Under Perform
2023-03-07	Hochstufung	Credit Suisse	Underperform → Neutral
2023-02-27	Fortgesetzt	BofA Securities	Neutral
2023-02-24	Hochstufung	Jefferies	Hold → Buy
2023-02-03	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Herabstufung	Credit Suisse	Neutral → Underperform
2022-05-05	Hochstufung	JP Morgan	Underweight → Neutral
2022-03-10	Eingeleitet	H.C. Wainwright	Buy
2021-10-19	Herabstufung	Credit Suisse	Outperform → Neutral
2021-10-14	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Herabstufung	Stifel	Buy → Hold
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-12	Herabstufung	Jefferies	Buy → Hold
2021-02-09	Herabstufung	Goldman	Neutral → Sell
2021-01-15	Herabstufung	BofA Securities	Buy → Neutral
2020-11-10	Hochstufung	Credit Suisse	Neutral → Outperform
2020-09-29	Fortgesetzt	JP Morgan	Underweight
2020-08-11	Herabstufung	Credit Suisse	Outperform → Neutral
2020-04-01	Fortgesetzt	BofA/Merrill	Buy
2020-03-17	Hochstufung	Citigroup	Neutral → Buy
2020-02-24	Herabstufung	Northland Capital	Outperform → Market Perform
2020-02-14	Herabstufung	Citigroup	Buy → Neutral
2019-09-16	Hochstufung	Goldman	Sell → Neutral
2019-05-29	Herabstufung	Goldman	Neutral → Sell
2019-05-06	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-04-26	Hochstufung	Goldman	Sell → Neutral
2019-03-13	Hochstufung	JP Morgan	Underweight → Neutral
2019-01-07	Bestätigt	Needham	Strong Buy
2018-12-13	Eingeleitet	Goldman	Sell
2018-10-29	Hochstufung	Northland Capital	Market Perform → Outperform
2018-10-16	Eingeleitet	BTIG Research	Buy
2018-08-17	Hochstufung	Citigroup	Neutral → Buy
2018-07-11	Herabstufung	Northland Capital	Outperform → Market Perform
2018-05-03	Herabstufung	JP Morgan	Neutral → Underweight
2018-05-02	Herabstufung	BofA/Merrill	Buy → Underperform

Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

08:00 AM

Trial tests cholesterol drug in kids with inherited high cholesterol - Stock Titan

08:00 AM

May 22, 2026

ESPR Stock Price, Quote & Chart | ESPERION THERAPEUTICS INC (NASDAQ:ESPR) - ChartMill

May 22, 2026

May 19, 2026

Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur - AD HOC NEWS

May 19, 2026

May 16, 2026

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm

May 15, 2026

May 14, 2026

Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization - Traders Union

May 14, 2026

Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent - AD HOC NEWS

May 14, 2026

ESPR Stock Surges 44% in a Month: Here's What You Need to Know - sharewise.com

May 14, 2026

Drugmaker Esperion gives new hires 260,000 stock units to join - Stock Titan

May 14, 2026

May 13, 2026

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 - The Manila Times

May 13, 2026

Esperion Announces Two New Analyses Supporting Bempedoic - GlobeNewswire

May 13, 2026

New cholesterol data in kids and statin-intolerant adults at EAS 2026 - Stock Titan

May 13, 2026

May 12, 2026

Needham Maintains Esperion Therapeutics(ESPR.US) With Hold Rating - Moomoo

May 12, 2026

Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News - Moomoo

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk - The Globe and Mail

May 11, 2026

May 10, 2026

Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives - Sahm

May 10, 2026

May 08, 2026

Esperion Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 08, 2026

Esperion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 08, 2026

Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR - Stock Titan

May 08, 2026

Hypercholesterolemia Treatment Market is expected to Hit US$ - openPR.com

May 08, 2026

May 07, 2026

Esperion Therapeutics Q1 2026 earnings preview - MSN

May 07, 2026

United StatesGoodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED - Mondaq

May 07, 2026

May 06, 2026

Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.

May 06, 2026

MSN Money - MSN

May 06, 2026

SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH - Sahm

May 06, 2026

May 05, 2026

BIOG's investee Esperion bought by ArchiMed for USD1 billion - marketscreener.com

May 05, 2026

Esperion (ESPR) was downgraded to a Hold Rating at Needham - The Globe and Mail

May 05, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill

May 05, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.

May 05, 2026

Needham downgrades Esperion Therapeutics (ESPR) - MSN

May 05, 2026

BioPharma Credit to Finance Archimed's Purchase of Biotech Growth Trust's Esperion Therapeutics - Moomoo

May 05, 2026

Esperion to be acquired by ARCHIMED - The Pharma Letter

May 05, 2026

PRN_FinancialWrapper - FinancialContent

May 05, 2026

May 04, 2026

Esperion Therapeutics Cut to Hold From Buy by Needham - Moomoo

May 04, 2026

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc.ESPR - The AI Journal

May 04, 2026

Jefferies Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.28 - Moomoo

May 04, 2026

H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Hold Rating, Maintains Target Price $3.16 - Moomoo

May 04, 2026

Jefferies Downgrades Esperion Therapeutics to Hold From Buy, Adjusts Price Target to $3.28 From $5 - marketscreener.com

May 04, 2026

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - FinancialContent

May 04, 2026

May 03, 2026

ESPR Jumps On ARCHIMED Buyout Deal And Nasdaq Exit Plan - StocksToTrade

May 03, 2026

May 02, 2026

Penny Stocks To Watch TodayMay 2nd - MarketBeat

May 02, 2026

ESPR Jumps As Esperion Agrees To $1.1B Archimed Buyout - timothysykes.com

May 02, 2026

A Quick Look at Today's Ratings for Esperion Therapeutics(ESPR.US), With a Forecast Between $3.16 to $3.28 - Moomoo

May 02, 2026

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

May 02, 2026